NCT06532253 Long-term Safety Trial with NVDX3
| NCT ID | NCT06532253 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Novadip Biosciences |
| Condition | Distal Radius Fractures |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-08-22 |
| Primary Completion | 2036-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 15 participants in total. It began in 2024-08-22 with a primary completion date of 2036-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
An study evaluating the long-term safety of all patients previously treated with NVDX3.
Eligibility Criteria
Inclusion Criteria: 1. Patient being implanted with NVDX3. 2. Previously participated to one of the NVDX3 core clinical trials. 3. Patient accepts to comply to a yearly follow-up safety visit for 10 additional years 4. Patient has understood and accepted to participate in the long-term follow-up study by signing the informed consent. Exclusion Criteria: No exclusion criteria are applicable.
Contact & Investigator
Torsten Gerich, MD
PRINCIPAL INVESTIGATOR
Centre Hospitalier du Luxembourg
Frequently Asked Questions
Who can join the NCT06532253 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Distal Radius Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06532253 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06532253 currently recruiting?
Yes, NCT06532253 is actively recruiting participants. Contact the research team at clinical@novadip.com for enrollment information.
Where is the NCT06532253 trial being conducted?
This trial is being conducted at Luxembourg, Luxembourg.
Who is sponsoring the NCT06532253 clinical trial?
NCT06532253 is sponsored by Novadip Biosciences. The principal investigator is Torsten Gerich, MD at Centre Hospitalier du Luxembourg. The trial plans to enroll 15 participants.